Search
Displaying 571–580 of 691 for “retinal diseases”
-
Eye on the Cure Podcast | Episode 45: Henry Klassen, MD, PhD
Eye on the CureApril 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte’s clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.
-
Fearless Sister Duo Finding Hope
Beacon StoriesApril LuFriu and Melissa Escobio are sisters and best friends who do just about everything together, including having retinitis pigmentosa (RP).
-
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
Research NewsThe company plans to seek FDA approval for the emerging therapy in first quarter of 2023
-
Kiora to Launch Clinical Trial in Australia for Vision-Restoring Small Molecule for RP Patients
Research NewsThe approach bestows light sensitivity to retinal ganglion cells for people who have lost their photoreceptors
-
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
Research NewsThe company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
Research NewsThe emerging treatment had shown encouraging results in a Phase ½ clinical trial
-
Beacon Stories
From stargazing to bird watching, Michael has been an enthusiast of all things science from the age of 12. When Michael was diagnosed with retinitis pigmentosa at 30 years old, he knew he wasn’t going to give up his dream of becoming a record-setting birder. In his own words, Michael shares how he’s overcome his vision loss and continued to pursue his birding passions with “birding-by-ear.”
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Interim Results Released for USH2A RNA Therapy Clinical Trial
Research NewsSuggestions of efficacy observed in 25 percent of participants receiving the treatment
